Instytut Zywnosci i Zywienia

Warsaw, Poland

Instytut Zywnosci i Zywienia

Warsaw, Poland
SEARCH FILTERS
Time filter
Source Type

Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: KBBE-2007-2-4-01;KBBE-2007-2-4-02 | Award Amount: 8.89M | Year: 2008

Flavouring, Additive and Food Contact Material Exposure Task: FACET FACET will deliver to the European Community a sustainable surveillance system, to estimate target food chemical intake. The project will consist of three main groupings of its 20 partners. The Chemicals group will prioritise the flavourings, additives and food contact materials for investigation and the food categories applicable to them. The Food group will take those food categories and will establish food ingredient occurrence data through the primary collection of food packaging material and the recording of all food ingredients in purchased foods. It will also create tired food consumption databases linked to the target food categories. In addition, where intake data is limited, models of regional diets will be developed. A group on chemical concentration will provide data on the concentration of target chemicals in target food groups. Databases on food intake, food chemical occurrence and food chemical concentration will be linked in algorithms which will be converted into computer code for the estimation of probabilistic exposure to target food chemical intake.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: KBBE.2010.2.3-02 | Award Amount: 12.29M | Year: 2011

The present proposal sees the development of business and value creation models as central to the development of personalised nutrition and thus it is intended to engage in a series of interviews with key stakeholders, which will generate a number of scenarios to be considered by these stakeholders. Parallel to that we will run some focus groups with consumers and develop a tool to ascertain consumer attitudes to personalised nutrition in 8 EU countries (1,000 per country) representing a breadth of gastronomic traditions. Within these 8 countries, we will recruit 1,280 subjects and offer 3 levels of personalised nutrition: 1 Personalised dietary advice alone; 2: personalised dietary advice based on biochemical phenotypic data; 3: the latter to include genomic data. These will be compared with a control group, which will be offered non-personalised dietary advice. All of the data on dietary intake and all of the advice will be Internet delivered and will last 6 months. Within each of the 3 levels of personalised nutrition groups, half will receive their feedback at months 0, 3 and 6 while the other half will have continuous feedback on demand with intensive coaching. The overall outcome measurement will be changes in a healthy eating index. The data gathered in this study will feed into the development of algorithms to provide automated feedback for future services delivering personalised advice on food choice. We will bring together an international group of experts to develop best practice in the application of all aspects of nutrigenomic research to personalised nutrition. We will also scope out existing and future technologies, particularly those involving biofeedback, which will help the development of personalised nutrition. Finally we develop position papers on the ethical and legal aspects of personalised nutrition. Permeating all of this work will be a wide-ranging communications programme aimed at all stakeholders of relevance to personalised nutrition.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: KBBE.2011.2.4-02 | Award Amount: 7.58M | Year: 2012

Total Diet Studies (TDS) allow getting information on real dietary exposure to food contaminants consumption (heavy metals, mycotoxins, POPs...) and estimating chronic exposure to pesticide residues in food and food additives intake. TDS consider total exposure from whole diets and are based on food contamination as consumed rather than contamination from raw commodities, thus ensuring a realistic exposure measure. TDS facilitate risk assessment (RA) and health monitoring (HM). Some EU Member States (MS) and Candidate Countries (CC) have no TDS programme or use various methods to collect data, which were not examined yet to tell whether they are comparable or not. This is of interest for EFSA or WHO-FAO. Similarly it is important to harmonise methods to assess dietary exposure risks in MS, CC and at the European level compared with other world regions. The methods proposed will aim for food sampling, standard analytical procedures, exposure assessment modelling, priority foods and selected chemical contaminants consistency across MS and CC. Various approaches and methods to identify sampling and analyses will be assessed and best practice defined. Contaminants and foods which contribute most to total exposure in European populations will be defined. Priority will be given to training and support in EU MS and CC currently without TDS. It will demonstrate best practice in creating a TDS programme using harmonised methods in regions previously lacking TDS, and ensure consistency of data collected. A database will be set up describing existing EU studies and collating harmonised exposure measures and designed to allow risk assessors and managers handling dietary exposure more accurately and more specifically. TDSEXPOSURE will spread excellence in TDS throughout stakeholders and establish a legacy of harmonised methods for sampling and analysis, and science-based recommendations for future global studies.


For many teenagers the time of growing up is a period of trying prohibited substances. Nowadays apart from alcohol and tobacco new designed, psychoactive substances known as "smart drugs" or "legal highs" are available. Intensive development of their market is taking place in the last few years which is difficult to overcome by regulations only. Toxicological tests used now are not able to detect the presence of many such substances in the body. Designer drugs cause the interest of young people even from small towns and many times taking them give effects requiring medical help. Caffeine is also a psychoactive substance but depending on the dose it can have positive or detrimental effect. Recently there are more and more products with caffeine, especially drinks and dietary supplements, what can cause the increase of consumption of caffeine. Children are particularly exposed to the adverse effect of high consumption of caffeine because of their small body weight and development of the central nervous system. This article presents actual data about the market of designer drugs, frequency of using them, consumption of caffeine by children and teenagers and about the impact of these substances on the organism.


Jarosz M.,Instytut Zywnosci i Zywienia | Traczyk I.,Instytut Zywnosci i Zywienia | Tomasiuk R.,Zaklad Diagnostyki Laboratoryjnej | Respondek W.,Instytut Zywnosci i Zywienia
Alergia Astma Immunologia | Year: 2011

Introduction. Many people declare abnormal symptoms after food intake. Up to 35% of general population and up to 67% of IBS patients claim that they suffer from food allergies. Aim of the study. Comparison of the incidence of specific IgE antibodies against selected food allergens in serum of the IBS patients and control group. Material and methods. The study was conducted among 150 IBS patients and 50 healthy subjects. At the first phase the concentration of sIgE against allergens contained in mixes was tested. Then sIgE concentration was analyzed against 8 allergens selected on the basis of the results of phase I and interviews with patients about products suspected as the cause of health problems. The antibody concentration was determined by enzyme immunoassay method. Results. Increased levels of sIgE occurred more frequently in the sera of healthy individuals than in IBS patients (93,5% vs. 70,1%). The most frequently elevated sIgE concentrations were found against allergens of egg, lemon (97%) and strawberries (93%) in IBS patients. In all patients in the control group elevated levels of IgE against allergens: egg white, rye, and lemons were found. Conclusions. The results did not confirm the hypothesis that higher levels of IgE against food allergens occur more frequently in the serum of IBS patients than in healthy subjects. Slightly increased concentrations of sIgE (below 3.5 IU/ml) in healthy individuals have no clinical significance. © Alergia Astma Immunologia 2011.


Wierzejska R.,Instytut Zywnosci i Zywienia
Medycyna wieku rozwojowego | Year: 2011

For young people energy drinks have become the new fashion and also a quick way to increase the fitness of the body. Lack of legal regulations gives freedom in active ingredients concentration, based sometimes on the principle "the more the better". In the literature there are increasing data about adverse effects of energy drinks consumption. Children and adolescents are the risk group for negative health consequences. This article is a comprehensive literature review on the effects of energy drinks on the developing human body and its health safety.


The severe hypercholesterolaemia can be recognised when low density lipoprotein cholesterol (LDL-C) serum levels are equal to or above 5 mmol/L (≥ 190 mg/dL). The prevalence of LDL-C. 5 mmol/L is 3.8% in Polish population aged 18.79 years. Among these adults there are patients with familial hypercholesterolaemia (FH). According to meta-analysis of 6 Polish population surveys prevalence of heterozygous FH (HeFH) diagnosed using Dutch Lipid Clinic criteria is 0.4% (95% Cl 0.28.0.53%) in men and women aged 20.74 years, i.e. one in every 250 people. As HeFH is a wellknown cause of premature coronary heart disease the rigorous treatment targets for LDL-C have been established in clinical guidelines. Their achivements, even with a high dose of high efficacy statin therapy is difficult or even imposible. New strong hypolipidaemic drugs i.e. PCSK9 inhibitors have been initiated against this chalange. Both drugs, evolocumab and alirocumab, have been extensively studied in numerous phase 2 and phase 3 trials. Fewer studies with bococizumab are available until now. The PCSK9 inhibitors, as monotherapy as well in combination with statins were associated with mean LDL-C reduction about 60%. It means that the majority of patients (70-90%) with severe hypercholesterolaemia (including HeFH), treated with statins, after addition of PCSK9 inhibitors were able to achive an LDL-C < 2.5 mmol/L (< 100 mg/dL) or < 1.8 mmol/L (< 70 mg/dL) level. Another group of patients who may benefit from PCSK9 inhibitors include those who need lipid lowering therapy, but who are statin intolerant, especially because of statin-associated muscle symptoms (SAMS). In our statement we have accepted the diagnosis of SAMS proposed recently by European Atherosclerosis Society. Today the longest clinical trial with evolocumab (11 months) was the open OSLER study, and with alirocumab ODYSSEY LONG TERM (78 weeks). In the first one the reduction of cardiovascular events by 53% (95% Cl 22-72%) was observed, and in the second one by 48% (10-69%). Neurocognitive events were reported more frequently with both drugs than with placebo. This adverse effect will be the subject of observation in ongoing studies. We still await the results of 4 ongoing large placebo controlled phase 3 trials investigating whether PCSK9 inhibitors on background of statin therapy reduce cardiovascular events. Meanwhile evolocumab, as well as alirocumab have been accepted to use in clinical practice by European Medicine Agency. In this situation the experts of Polish Society of Cardiology have prepared the statement on the use PCSK9 inhibitors with indication in the first place for HeFH patients, statin intolerant and those at high risk who are not able to reach LDL-C target level with a high potent high dose statin. Copyright © Polskie Towarzystwo Kardiologiczne 2016.


PubMed | Instytut Zywnosci i Zywienia
Type: Journal Article | Journal: Developmental period medicine | Year: 2014

For many teenagers the time of growing up is a period of trying prohibited substances. Nowadays apart from alcohol and tobacco new designed, psychoactive substances known as smart drugs or legal highs are available. Intensive development of their market is taking place in the last few years which is difficult to overcome by regulations only. Toxicological tests used now are not able to detect the presence of many such substances in the body. Designer drugs cause the interest of young people even from small towns and many times taking them give effects requiring medical help. Caffeine is also a psychoactive substance but depending on the dose it can have positive or detrimental effect. Recently there are more and more products with caffeine, especially drinks and dietary supplements, what can cause the increase of consumption of caffeine. Children are particularly exposed to the adverse effect of high consumption of caffeine because of their small body weight and development of the central nervous system. This article presents actual data about the market of designer drugs, frequency of using them, consumption of caffeine by children and teenagers and about the impact of these substances on the organism.


PubMed | Instytut Zywnosci i Zywienia
Type: Journal Article | Journal: Medycyna wieku rozwojowego | Year: 2012

For young people energy drinks have become the new fashion and also a quick way to increase the fitness of the body. Lack of legal regulations gives freedom in active ingredients concentration, based sometimes on the principle the more the better. In the literature there are increasing data about adverse effects of energy drinks consumption. Children and adolescents are the risk group for negative health consequences. This article is a comprehensive literature review on the effects of energy drinks on the developing human body and its health safety.


The severe hypercholesterolaemia can be recognised when low density lipoprotein cholesterol (LDL-C) serum levels are equal to or above 5 mmol/L ( 190 mg/dL). The prevalence of LDL-C 5 mmol/L is 3.8% in Polish population aged 18-79 years. Among these adults there are patients with familial hypercholesterolaemia (FH). According to meta-analysis of 6 Polish population surveys prevalence of heterozygous FH (HeFH) diagnosed using Dutch Lipid Clinic criteria is 0.4% (95% Cl 0.28-0.53%) in men and women aged 20-74 years, i.e. one in every 250 people. As HeFH is a wellknown cause of premature coronary heart disease the rigorous treatment targets for LDL-C have been established in clinical guidelines. Their achievements, even with a high dose of high efficacy statin therapy is difficult or even impossible. New strong hypolipidaemic drugs i.e. PCSK9 inhibitors have been initiated against this chalange. Both drugs, evolocumab and alirocumab, have been extensively studied in numerous phase 2 and phase 3 trials. Fewer studies with bococizumab are available until now. The PCSK9 inhibitors, as monotherapy as well in combination with statins were associated with mean LDL-C reduction about 60%. It means that the majority of patients (70-90%) with severe hypercholesterolaemia (including HeFH), treated with statins, after addition of PCSK9 inhibitors were able to achieve an LDL-C < 2.5 mmol/L (< 100 mg/dL) or < 1.8 mmol/L (< 70 mg/dL) level. Another group of patients who may benefit from PCSK9 inhibitors include those who need lipid lowering therapy, but who are statin intolerant, especially because of statin-associated muscle symptoms (SAMS). In our statement we have accepted the diagnosis of SAMS proposed recently by European Atherosclerosis Society. Today the longest clinical trial with evolocumab (11 months) was the open OSLER study, and with alirocumab ODYSSEY LONG TERM (78 weeks). In the first one the reduction of cardiovascular events by 53% (95% Cl 22-72%) was observed, and in the second one by 48% (10-69%). Neurocognitive events were reported more frequently with both drugs than with placebo. This adverse effect will be the subject of observation in ongoing studies. We still await the results of 4 ongoing large placebo controlled phase 3 trials investigating whether PCSK9 inhibitors on background of statin therapy reduce cardiovascular events. Meanwhile evolocumab, as well as alirocumab have been accepted to use in clinical practice by European Medicine Agency. In this situation the experts of Polish Society of Cardiology have prepared the statement on the use PCSK9 inhibitors with indication in the first place for HeFH patients, statin intolerant and those at high risk who are not able to reach LDL-C target level with a high potent high dose statin.

Loading Instytut Zywnosci i Zywienia collaborators
Loading Instytut Zywnosci i Zywienia collaborators